Asymmetrie synthesis of a potent, aminopiperidine-fused imidazopyridine dipeptidyl peptidase IV inhibitor

Journal of Organic Chemistry

Volumn 75, Issue 5, 2010, Pages 1343-1353

  Xu, Feng ^a   Corley, Edward ^a   Zacuto, Michael ^a   Conlon, David A ^a   Pipik, Brenda ^a   Humphrey, Guy ^a   Jerry Murry, D ^a   Tschaen, David ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASYMMETRIC SYNTHESIS; CATALYZED COUPLING; DIESTERS; DIMETHYL MALONATE; DIPEPTIDYL PEPTIDASE; DYNAMIC CRYSTALLIZATION; ENAMINE INTERMEDIATES; ENANTIOSELECTIVE MICHAEL ADDITION; EPIMERIZATION; FUNCTIONALIZED; HIGH YIELD; IMIDAZOPYRIDINES; KINETIC CONTROL; LARGE SCALE PREPARATION; NITRO GROUP; NITROSTYRENE; ONE POT; REACTION SOLUTIONS; STEREOGENIC CENTERS; THREE-COMPONENT; TRACE AMOUNTS; TRANS ISOMERS; TRANSAMIDATION; TRICYCLIC STRUCTURE;

ADDITION REACTIONS; CYCLIZATION; ELECTRON TRANSITIONS; ISOMERS; RHODIUM COMPOUNDS;

SYNTHESIS (CHEMICAL);

1 5 BITRO 4 (TRIFLUOROPHENYL)PIPERIDIN 2 ONE; 6 OXO 4 (2,4,5 TRIFLUOROPHENYL)PIPERIDIN 3 YLAMMONIUM TOLUENE 4 SULFONATE; AMINOPIPERIDINE; ENAMINE; IMIDAZOPYRIDINE DERIVATIVE; IMIDAZOPYRIDINE DIPEPTIDYL PEPTIDASE IV INHIBITOR; LACTAM; METHYLMALONIC ACID; PIPERIDINE DERIVATIVE; SODIUM CHLORIDE; SULFONIC ACID DERIVATIVE; UNCLASSIFIED DRUG; (R) 7 (2,4,5 TRIFLUOROPHENYL) 5,6,7,8 TETRAHYDRO 2,4B DIAZAFLUOREN 6 YLAMINE; (R)-7-(2,4,5-TRIFLUOROPHENYL)-5,6,7,8-TETRAHYDRO-2,4B-DIAZAFLUOREN-6-YLAMINE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; FUSED HETEROCYCLIC RINGS; PIPERIDONE DERIVATIVE;

ARTICLE; CRYSTALLIZATION; CYCLIZATION; DRUG STRUCTURE; EPIMERIZATION; HYDROLYSIS; ISOMERIZATION; KINETICS; MICHAEL ADDITION; SYNTHESIS; CATALYSIS; CHEMICAL STRUCTURE; CHEMISTRY; CONFORMATION; GEL CHROMATOGRAPHY; ISOMERISM; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; X RAY CRYSTALLOGRAPHY;

CATALYSIS; CHROMATOGRAPHY, GEL; CRYSTALLOGRAPHY, X-RAY; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; HETEROCYCLIC COMPOUNDS, 3-RING; ISOMERISM; MAGNETIC RESONANCE SPECTROSCOPY; MOLECULAR CONFORMATION; MOLECULAR STRUCTURE; PIPERIDONES;

EID: 77949287444     PISSN: 00223263     EISSN: 15206904     Source Type: Journal    
DOI: 10.1021/jo902573q     Document Type: Article

References (76)

1. a) International Diabetes Federation (IDF). Diabetes Atlas, 3rd ed.; December 2006, http://www.iotf.org/diabetes.asp.
2. b) Andrews, M. U.S. News World Rep., 2009, Feb 9.
3. Zimmet, P.; Alberti, K. G. M. M.; Shaw, J. Nature 2001, 414, 782-787.
4. For leading references, see: (a) Thornberry, N. A.: Weber. A. E. Curr. Tonics Med. Chem. 2007, 7, 557-568.
5. b) Gwaltney, S. L. II; Stafford, J. A. Annu. Rep. Med. Chem. 2005, 40, 149-165.
6. c) Ahrén, B.; Landin-Olsson, M.; Jansson, P. A.; Svenson, M.; Holmes, D.; Schweizer, A. J. Clin. Endocrinol. Metab. 2004, 89, 2078-2084.
7. d) Weber, A. J. Med. Chem. 2004, 48, 4135-4141.
8. a) Florentin, M.; Liberopoulos, E. N.; Mikhailidis, D. P.; Elisaf, M. S. Expert Opin. Pharmacother. 2008, 9, 1705-1720.
9. b) Matikainen, N.; Mänttäri, S.; Schwizer, A. Diabetologia 2006, 49, 2049-2057.
10. For review, see: Hoist, J. J. Diabetogoia 2006, 49, 253-260.
11. For lead references, see: (a) Chia, C. W.; Egan, J. M. Drug Discovery Today: Disease Mech. 2005, 2, 295.
12. b) Holst, J. J. Curr. Opin. Endocrin. Diabetes Obesity 2005, 12, 56-62.
13. a) Edmondson, S. D.; Mastracchio, A.; Cox, J. M.; Eiermann, G. J.; He, H.; Lyons, K. A.; Patel, R. A.; Patel, S. B.; Petrov, A.; Scapin, G.; Wu, J. K.; Xu, S.; Zhu, B.; Thornberry, N. A.; Roy, R. S.; Weber, A. E. Bioorg. Med. Chem. Lett. 2009, 19, 4097-4101.
14. b) Cox, J. M.; Edmondson, S. D.; Harper, B.; Weber, A. E. PCT Int. Appl. WO2006039325, 2006.
15. For recent reviews, see: (a) Leiais, G.; MacMillan, D. W. C. Aldrichim. Acta 2006, 39, 79-87.
16. b) Palomo, C.; Mielgo, A. Angew. Chem., Int. Ed. 2006, 45, 7876-7880.
17. For a lead reference on metal-assisted coupling for the formation of amides, see: Klapars, A.; Huang, X.; Buchwald, S. L. J. Am. Chem. Soc. 2002, 124, 7421-7428.
18. In fact, piperidinones such as 4 are pharmaceutically useful intermediates. For examples, see: (a) Cox, J. M.; Harper, B.; Mastracchio, A.; Leiting, B.; Roy, R. S.; Patel, R. A.; Wu, J. K.; Lyons, K. A.; He, H.; Xu, S.; Zhu, B.; Thornberry, N. A.; Weber, A. E.; Edmondson, S. D. Bioorg. Med. Chem. Lett. 2007, 17, 4579-4583.
19. b) Pei, Z.; Li, X.; von Geldern, T. W.; Longenecker, K.; Pireh, D.; Stewart, K. D.; Backes, B. J.; Lai, C.; Lubben, T. H.; Ballaron, S. J.; Beno, D. W. A.; Kempf-Grote, A. J.; Sham, H. L.; Trevillyan, J. M. J. Med. Chem. 2007, 50, 1983-1987.
20. c) Edmondson, S. D.; Mastracchio, A.; Cox, J. M. PCT Int. Appl. WO2006058064, 2006.
21. d) Ashwell, S.; Gero, T.; Ioannidis, S.; Janetka, J.; Lyne, P.; Su, M.; Toader, D.; Yu, D.; Yu, Y. PCT Int. Appl. WO2005066163, 2005.
22. e) Cody, W. L.; Holsworth, D. D.; Powell, N. A.; Jalaie, M.; Zhang, E.; Wang, W.; Samas, B.; Bryant, J.; Ostraski, R.; Ryan, M. J.; Edmunds, J. J. Bio. Med. Chem. 2004, 13, 59-68.
23. For a preliminary communication on cascade coupling, see: Xu, F.; Corley, E.; Murry, J. A.; Tschaen, D. M. Org. Lett. 2007, 9, 2669-2672.
24. For examples, see: (a) Terada, M.; Ube, H.; Yaguchi, Y. J. Am. Chem. Soc. 2006, 128, 1454-1455.
25. b) Evans, D. A.; Seidel, D. J. Am. Chem. Soc. 2005, 127, 9958-9959.
26. c) Okino, T.; Hoashi, Y.; Furukawa, T.; Xu, X.; Takemoto, Y. J. Am. Chem. Soc. 2005, 127, 119-125.
27. d) Li, H.; Wang, Y.; Tang, L.; Deng. L. J. Am. Chem. Soc. 2004, 127, 9906-9907.
28. e) Watanabe, M.; Ikagawa, A.; Wang, H.; Murata, K.; Ikariya, T. J. Am. Chem. Soc. 2004, 126, 11148-11149.
29. f) Ji, J.; Barnes, D. M.; Zhang, J.; King, S. A.; Wittenberger, S. J.; Morton, H. E. J. Am. Chem. Soc. 1999, 121, 10215-10216.
30. g) Hynes, P. S.; Stupple, P. A.; Dixon, D. J. Org. Lett. 2008, 10, 1389-1391.
31. h) Zhu, Q.; Huang, H.; Shi, D.; Shen, Z.; Xia, C. Org. Lett. 2009, 11, 4536-4539.
32. One-pot synthesis led to a low yield of fluoro-substituted styrenes; see: Jacobo, R.; Cota, A.; Rogel, E.; Garcia, J. D.; Rivero, I. A.; Hellberg, L. H.; Somanathan, R. J. Fluorine Chem. 1994, 67, 253-255.
33. For examples, see: (a) Denmark, S. E.; Marcin, L. R. J. Org. Chem. 1993, 58, 3850-3856.
34. b) Saikia, A. K.; Barua, N. C.; Sharma, R. P.; Ghosh, A. C. Synthesis 1994, 685-686.
35. 2NEt, DBU, and tetramethylguanidine in various solvents resulted in unsatisfactory results.
36. a) Anderson, W. K.; Dabrah, T. T.; Houston, D. M. J. Org. Chem. 1987, 52, 2945-2947.
37. b) Worrall, D. E. et al. Organic Synthesis; Wiley: New York, 1941; Collect. Vol. 1, p 413.
38. 2 to enhance the selectivity of the formation of nitro styrenes has not been reported.
39. For an improved, practical preparation of DMQ without chromatographic purification, see the Supporting Information.
40. For examples, see: Kumar, S.; Flamant-Robin, C.; Wan, Q.; Chiaroni, A.; Sasaki, N. A. j. Org. Chem. 2005, 70, 5946-5953 and references therein
41. For similar three-component couplings, see: (a) Nara, S.; Tanaka, R.; Eishima, J.; Hara, M.; Takahashi, Y.; Otaki, S.; Foglesong, R. J.; Hughes, P. F.; Turkington, S.; Kanda, Y. J. Med. Chem. 2003, 46, 2467-2473.
42. b) Desai, M. C.; Lefkowitz, S. L. Bioorg. Med. Chem. Lett. 1993, 3, 2083-2086.
43. c) Desai, M. C.; Thadeio, P. F.; Lefkowitz, S. L. Tetrahedron Lett. 1993, 34, 5831-5834.
44. d) Bhagwatheeswaran, H.; Gaur, S. P.; Jain, P. C. Synthesis 1976, 615-616.
45. For recent examples of multiple-component coupling involving nitroalkane or amine/formaldehyde, see: (a) Enders, D.; Hüttlm, M. R. M.; Grondai, C.; Raabe, G. Nature 2006, 441, 861-863.
46. b) Sundén, H.; Ibrahcm, I.; Eriksson, L.; Cordova, A. Angew. Chem., Int. Ed. 2005, 44, 4877-4880 and references therein.
47. Overman, L. E.; Burk, R. M. Tetrahedron Lett. 1984, 25, 1635-1638.
48. For an alternative synthesis as well as optimization of the cascade reaction using 4-methoxybenzyl amine, see the Supporting Information.
49. 3, see: Zacuto, M. J.; Xu, F. J. Org. Chem. 2007, 72, 6298-6300. However, deprotection of N-allyl lactams as described here gave a mixture of deprotected lactam 17 and N,O-acetal lactam. 18.
50. Presumably due to the less nucleophilic aryl amine nitrogen, the cascade coupling stalled at intermediate 1.3 when aryl amines such as 4-methoxyphenylamine were used. The formation of 13a thus further supports the stepwise reaction pathway (Scheme 3). Chemical Equetion Presentation
51. It is not very clear why the cis isomer is the major product through acidic equilibrium. Presumably, the formation of the cis isomer is kinetically favored under acidic conditions.
52. 4/MeCN).
53. Hudlický, M. Reductions in Organic Chemistry, 2nd ed.; ACS Monograph 188; American Chemical Society: Washington, DC, 1996.
54. Greene, T. W.; Wuts, P. G. M. Protective Groups in Organic Synthesis, 3rd ed.; John Wiley & Sons, Inc.: New York, 1999.
55. a) Stille, J. K.; Becker, Y. J. Org. Chem. 1980, 45, 2139-2145.
56. b) Nemeto, H.; Jimenez, H. N.; Yamamoto, Y. Chem. Commun. 1990, 1304-6.
57. c) Kanno, O.; Miyauchi, M.; Kawamoto, I. Heterocycles 2000, 53, 173-181.
58. d) Cainelli, G.; Giacomini, D.; Galetti, P. Synthesis 2000, 289-294.
59. e) Cainelli, G.; DaCol, M.; Galetti, P.; Giacomini, D. Synlett 1997, 923-924.
60. f) Chiusoli, G. P.; Costa, M.; Fiore, A. Chem. Commun. 1990, 1303-1304.
61. a) Alcaide, B.; Almendros, P.; Alonso, J. M.; Aly, M. F. Org. Lett. 2001, 3, 3781-3784.
62. b) Alcaide, B.; Almendros, P.; Alonso, J. M. Tetrahedron. Lett. 2003, 44, 8693-8695.
63. c) For a report on the Ru-catalyzed isomerization but not applied to N-allyl deprotection, see: Krompiec, S.; Pigulla, M.; Krompiec, M.; Baj, S.; Mrowiec-Bialon, J.; Kasperczyk, J. Tetrahedron Lett. 2004, 45, 5257-5261.
64. Attempts to hydrolyze 19 under acidic conditions resulted in epimerization of the stereogenic center adjacent to nitro group. In addition, subsequent hydrogenation would also reduce enamine 19 to the undesired corresponding n-propyl lactam.
65. For relevant observations, see: (a) Cramer, R. J. Am. Chem. Soc. 1967, 89, 1633-1639 and references therein.
66. b) Trebellas, J. C.; Olechowski, J. R.; Jonasscn, H. B.; Moore, D. W. J. Organomet. Chem. 1967, 9, 153.
67. c) Hirai, H.; Sawai, H.; Ochiai, E.-I.; Makishima, S. J. Catal. 1970, 17, 119.
68. d) Su, A. C. Adv. Organomet. Chem. 1979, 17, 269. These mechanistic studies, including deuterium labeling experiments, suggest a Rh(I) hydride species is likely the active catalyst, since Rh(III) is reduced to Rh(I) in the presence of olefins and alcohol solvents.
69. 3 with alcohol solvents was also observed in our previous communication, cf. ref 24.
70. For examples of intramolecular transamidation, see: (a) Tanaka, K.-I.; Nemoto, H.; Sawanishi, H. Tetrahedron: Asymmetry 2005, 16, 809-815.
71. b) Langlois, N. Org. Lett. 2002, 4, 185-187.
72. c) Langlois, N. Tetrahedron. Lett. 2002, 43, 9531-9533.
73. Although isolation of 24 and 26 from the reaction mixture was difficult, their structures could be unambiguously characterized by applying NMR techniques.
74. a) Stockmann, V.; Fiksdahl, A. Tetrahedron 2008, 64, 7626-7632.
75. b) Tjosaas, F.; Kjerstad, I. B.; Fiksdahl, A. J. Heterocycl. Chem. 2008, 45, 559-562 and references cited therein.
76. For this specific compound, the sample concentration would also affect the observed chemical shifts.